Validation of suPAR turbidimetric assay on Cobas® (c502 and c702) and comparison to suPAR ELISA

References

• Desmedt S, Desmedt V, Delanghe JR, et al. The intriguing role of soluble urokinase receptor in inflammatory diseases. Crit Rev Clin Lab Sci. 2017;54(2):117–133.
   PubMed Web of Science ®Google Scholar
• Sidenius N, Sier CF, Ullum H, et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood. 2000;96(13):4091–4095.
   PubMed Web of Science ®Google Scholar
• Rudolf F, Wagner AJ, Back FM, et al. Tuberculosis case finding and mortality prediction: added value of the clinical TBscore and biomarker suPAR. Int J Tuberc Lung Dis. 2017;21(1):67–72.
   PubMed Web of Science ®Google Scholar
• Tzanakaki G, Paparoupa M, Kyprianou M, et al. Elevated soluble urokinase receptor values in CSF, age and bacterial meningitis infection are independent and additive risk factors of fatal outcome. Eur J Clin Microbiol Infect Dis. 2012;31(6):1157–1162.
   PubMed Web of Science ®Google Scholar
• Ostergaard C, Benfield T, Lundgren JD, et al. Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. Scand J Infect Dis. 2004;36:14–19.
   PubMed Web of Science ®Google Scholar
• Wrotek A, Jackowska T. The role of the soluble urokinase plasminogen activator (suPAR) in children with pneumonia. Respir Physiol Neurobiol. 2015;209:120–123.
   PubMed Web of Science ®Google Scholar
• Savva A, Raftogiannis M, Baziaka F, et al. Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis. J Infect. 2011;63(5):344–350.
   PubMed Web of Science ®Google Scholar
• Backes Y, van der Sluijs KF, Mackie DP, et al. Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Med. 2012;38(9):1418–1428.
   PubMed Web of Science ®Google Scholar
• Donadello K, Scolletta S, Covajes C, et al. suPAR as a prognostic biomarker in sepsis. BMC Med. 2012;10(1):2.
   PubMed Web of Science ®Google Scholar
• Donadello K, Scolletta S, Taccone FS, et al. Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients. J Crit Care. 2014;29(1):144–149.
   PubMed Web of Science ®Google Scholar
• Koch A, Voigt S, Kruschinski C, et al. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care. 2011;15(1):R63.
   PubMed Web of Science ®Google Scholar
• Suberviola B, Castellanos-Ortega A, Ruiz Ruiz A, et al. Hospital mortality prognostication in sepsis using the new biomarkers suPAR and proADM in a single determination on ICU admission. Intensive Care Med. 2013;39(11):1945–1952.
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Georgitsi M. Host response biomarker in sepsis: suPAR detection. Methods Mol Biol. 2015;1237:241–246.
   PubMedGoogle Scholar
• Giamarellos-Bourboulis EJ, Norrby-Teglund A, Mylona V, et al. Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor. Crit Care. 2012;16(4):R149.
   PubMed Web of Science ®Google Scholar
• Edsfeldt A, Nitulescu M, Grufman H, et al. Soluble urokinase plasminogen activator receptor is associated with inflammation in the vulnerable human atherosclerotic plaque. Stroke. 2012;43(12):3305–3312.
   PubMed Web of Science ®Google Scholar
• Lyngbaek S, Marott JL, Møller DV, et al. Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention. Am J Cardiol. 2012;110(12):1756–1763.
   PubMed Web of Science ®Google Scholar
• Rundgren M, Lyngbaek S, Fisker H, et al. The inflammatory marker suPAR after cardiac arrest. Ther Hypothermia Temp Manag. 2015;5(2):89–94.
   PubMed Web of Science ®Google Scholar
• Jalkanen V, Vaahersalo J, Pettila V, et al. The predictive value of soluble urokinase plasminogen activator receptor (SuPAR) regarding 90-day mortality and 12-month neurological outcome in critically ill patients after out-of-hospital cardiac arrest. Data from the prospective FINNRESUSCI study. Resuscitation. 2014;85(11):1562–1567.
   PubMed Web of Science ®Google Scholar
• Engstrom G, Zoller B, Svensson PJ, et al. Soluble urokinase plasminogen activator receptor and incidence of venous thromboembolism. Thromb Haemost. 2016;115:657–662.
   PubMed Web of Science ®Google Scholar
• Persson M, Ostling G, Smith G, et al. Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease. Stroke. 2014;45(1):18–23.
   PubMed Web of Science ®Google Scholar
• Fuhrman B. The urokinase system in the pathogenesis of atherosclerosis. Atherosclerosis. 2012;222(1):8–14.
   PubMed Web of Science ®Google Scholar
• Zimmermann HW, Koch A, Seidler S, et al. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis. Liver Int. 2012;32:500–509.
   PubMed Web of Science ®Google Scholar
• Wiese S, Mortensen C, Gotze JP, et al. Cardiac and proinflammatory markers predict prognosis in cirrhosis. Liver Int. 2014;34(6):e19–e30.
   PubMed Web of Science ®Google Scholar
• Tuomi H, Kultti J, Danielsson J, et al. Serum soluble urokinase plasminogen activator receptor in alcoholics: relation to liver disease severity, fibrogenesis, and alcohol use. J Gastroenterol Hepatol. 2014;29(12):1991–1995.
   PubMed Web of Science ®Google Scholar
• Sjowall C, Martinsson K, Cardell K, et al. Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease. Transl Res. 2015;165:658–666.
   PubMed Web of Science ®Google Scholar
• Zimmermann HW, Reuken PA, Koch A, et al. Soluble urokinase plasminogen activator receptor is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality. J Intern Med. 2013;274(1):86–100.
   PubMed Web of Science ®Google Scholar
• Nikkola A, Aittoniemi J, Huttunen R, et al. Plasma level of soluble urokinase-type plasminogen activator receptor predicts the severity of acute alcohol pancreatitis. Pancreas. 2017;46(1):77–82.
   PubMed Web of Science ®Google Scholar
• Chounta A, Ellinas C, Tzanetakou V, et al. Serum soluble urokinase plasminogen activator receptor as a screening test for the early diagnosis of hepatocellular carcinoma. Liver Int. 2015;35(2):601–607.
   PubMed Web of Science ®Google Scholar
• Koch A, Zimmermann HW, Gassler N, et al. Clinical relevance and cellular source of elevated soluble urokinase plasminogen activator receptor (suPAR) in acute liver failure. Liver Int. 2014;34(9):1330–1339.
   PubMed Web of Science ®Google Scholar
• Meijers B, Maas RJ, Sprangers B, et al. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney Int. 2014;85(3):636–640.
   PubMed Web of Science ®Google Scholar
• Hayek SS, Sever S, Ko YA, et al. Soluble urokinase receptor and chronic kidney disease. N Engl J Med. 2015;373(20):1916–1925.
   PubMed Web of Science ®Google Scholar
• Musetti C, Quaglia M, Cena T, et al. Circulating suPAR levels are affected by glomerular filtration rate and proteinuria in primary and secondary glomerulonephritis. J Nephrol. 2015;28(3):299–305.
   PubMed Web of Science ®Google Scholar
• Konigshausen E, Sellin L. Circulating permeability factors in primary focal segmental glomerulosclerosis: a review of proposed candidates. Biomed Res Int. 2016;2016:3765608.
   PubMed Web of Science ®Google Scholar
• Lomholt AF, Hoyer-Hansen G, Nielsen HJ, et al. Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer. Br J Cancer. 2009;101(6):992–997.
   PubMed Web of Science ®Google Scholar
• Usnarska-Zubkiewicz L, Strutynska-Karpinska M, Zubkiewicz-Kucharska A, et al. Soluble urokinase-type plasminogen activator receptor and ferritin concentration in patients with advanced alimentary tract carcinoma. Relationship to localization, surgical treatment and the stage of the disease–preliminary report. Adv Clin Exp Med. 2014;23(6):959–967.
   PubMed Web of Science ®Google Scholar
• Jing J, Zheng S, Han C, et al. Evaluating the value of uPAR of serum and tissue on patients with cervical cancer. J Clin Lab Anal. 2012;26(1):16–21.
   PubMed Web of Science ®Google Scholar
• Cobos E, Jumper C, Lox C. Pretreatment determination of the serum urokinase plasminogen activator and its soluble receptor in advanced small-cell lung cancer or non-small-cell lung cancer. Clin Appl Thromb Hemost. 2003;9(3):241–246.
   PubMed Web of Science ®Google Scholar
• Henic E, Borgfeldt C, Christensen IJ, et al. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. Clin Cancer Res. 2008;14(18):5785–5793.
   PubMed Web of Science ®Google Scholar
• Sorio C, Mafficini A, Furlan F, et al. Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group. BMC Cancer. 2011;11(1):448.
   PubMed Web of Science ®Google Scholar
• Rubio-Jurado B, Tello-Gonzalez A, Bustamante-Chavez L, et al. Circulating Levels of Urokinase-Type Plasminogen Activator Receptor and D-Dimer in Patients With Hematological Malignancies. Clin Lymphoma Myeloma Leuk. 2015;15(10):621–626.
   PubMed Web of Science ®Google Scholar
• Haugaard SB, Andersen O, Hansen TW, et al. The immune marker soluble urokinase plasminogen activator receptor is associated with new-onset diabetes in non-smoking women and men. Diabet Med. 2012;29(4):479–487.
   PubMed Web of Science ®Google Scholar
• Heraclides A, Jensen TM, Rasmussen SS, et al. The pro-inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) is associated with incident type 2 diabetes among overweight but not obese individuals with impaired glucose regulation: effect modification by smoking and body weight status. Diabetologia. 2013;56:1542–1546.
   PubMed Web of Science ®Google Scholar
• Theilade S, Lyngbaek S, Hansen TW, et al. Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes. J Intern Med. 2015;277(3):362–371.
   PubMed Web of Science ®Google Scholar
• Thuno M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers. 2009;27:157–172.
   PubMed Web of Science ®Google Scholar
• Rasmussen LJH, Ladelund S, Haupt TH, et al. Combining national early warning score with soluble urokinase plasminogen activator receptor (suPAR) improves risk prediction in acute medical patients: a registry-based cohort study. Crit Care Med. 2018;46(12):1961–1968.
   PubMed Web of Science ®Google Scholar
• Rasmussen LJ, Ladelund S, Haupt TH, et al. Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study. Emerg Med J. 2016;33(11):769–775.
   PubMed Web of Science ®Google Scholar
• Schultz M, Rasmussen LJH, Hoi-Hansen T, et al. Early discharge from the emergency department based on soluble urokinase plasminogen activator receptor (suPAR) levels: a TRIAGE III substudy. Dis Markers. 2019;2019:1–8.
   Web of Science ®Google Scholar
• Kofoed K, Eugen-Olsen J, Petersen J, et al. Predicting mortality in patients with systemic inflammatory response syndrome: an evaluation of two prognostic models, two soluble receptors, and a macrophage migration inhibitory factor. Eur J Clin Microbiol Infect Dis. 2008;27(5):375–383.
   PubMed Web of Science ®Google Scholar
• Winnicki W, Sunder-Plassmann G, Sengölge G, et al. Diagnostic and prognostic value of soluble urokinase-type plasminogen activator receptor (suPAR) in focal segmental glomerulosclerosis and impact of detection method. Sci Rep. 2019;9(1):9.
   PubMed Web of Science ®Google Scholar
• Chew-Harris J, Appleby S, Richards AM, et al. Analytical, biochemical and clearance considerations of soluble urokinase plasminogen activator receptor (suPAR) in healthy individuals. Clin Biochem. 2019;69:36–44.
   PubMed Web of Science ®Google Scholar
• CLSI. EP05-A3, Evaluation of precision of quantitative measurement procedures; Approved Guideline. 3rd ed. 2014.Available from: https://clsi.org/standards/products/method-evaluation/documents/ep05/
   Google Scholar
• Laboratory C, Institute S. EP09-A3: measurement Procedure comparison and bias estimation using patient samples; Approved Guideline; 2013. Available from: https://clsi.org/standards/products/method-evaluation/documents/ep09/
   Google Scholar
• Institute CLS. Evaluation of detection capability for clinical laboratory, measurement procedures; Approved Guideline EP17-A2. Wayne (PA): Clinical and Laboratory Standards Institute (CLSI); 2012.
   Google Scholar
• DEKS. Danish Institute for External Quality Assurance for Laboratories in Health Care. Rigshospitalet-Glostrup, Valdemar Hansens Vej 1-23, indgang 8,1., 2600 Glostrup, DK. DEKS; 2019. Available from: http://deks.dk/en/about-deks-3/
   Google Scholar